Loading data
CLYMNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development expense | 46.71 m USD | 14.34 m USD | 15.41 m USD | 26.21 m USD | 23.32 m USD |
| Operating profit | -67.88 m USD | -82.02 m USD | -40.28 m USD | -45.14 m USD | -35.67 m USD |
| Income tax expense | 0 USD | 0 USD | 0 USD | 0 USD | 0 USD |
| Net income (reported basis) | -59.85 m USD | -73.9 m USD | -35.12 m USD | -45.24 m USD | -47.48 m USD |
| Net income attributable to common shareholders | — | — | — | -45.24 m USD | -52.03 m USD |
| Basic earnings per share | -0.88 USD/share | -1.53 USD/share | -1.3 USD/share | -1.72 USD/share | -4.24 USD/share |
| Diluted earnings per share | -0.88 USD/share | -1.53 USD/share | -1.3 USD/share | -1.72 USD/share | -4.24 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.